Reduced Lysosomal Acid Lipase Activity in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Current Evidence and Future Directions
Author(s)
Bashir A1, Tiwari P2, Duseja A3, Verma A4, De A3
1National Institute of Pharmaceutical Education and Research (NIPER), Rupnagar, PB, India, 2National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India, 3PGIMER Chandigarh, Chandigarh, UP, India, 4National Institute of Pharmaceutical Education and Research (NIPER), Saharanpur, UP, India
Presentation Documents
OBJECTIVES
: Non-alcoholic fatty liver disease (NAFLD) presents with accumulation of excessive intra-hepatic fat and acts as a major health burden globally. A multifactorial pathogenesis is reported to be involved. Reduced Lysosomal Acid Lipase (LAL) activity is suggested as one of the involved pathogenic mechanisms. This review summarizes the available evidence on role of reduced LAL activity in the pathogenesis of NAFLD.METHODS
: Four databases namely, PubMed/Medline, Science direct, Cochrane Library and Google scholar were searched to identify relevant observational records evaluating the role of LAL activity in pathogenesis of NAFLD. All studies were assessed for their quality by using Newcastle–Ottawa Scale (NOS) or The Joanna Briggs Institute (JBI) Critical Appraisal tools for cohort and cross-sectional studies, respectively. The estimates of LAL activity and other clinical outcomes were expressed as mean (SD) and number (%) as presented in the primary studies.RESULTS
: A total of nine good quality studies with 1711 NAFLD patients and 877 controls from different groups (healthy volunteers, alcoholics, cryptogenic cirrhosis and HCV-positive) were included. From the NAFLD group, 59.55% were males and the overall mean age ranged between the studies from 12.6±8.5 months in paediatrics to 58.90±13.82 years in adults. In the NAFLD group, the LAL activity varied from 0.53±0.08 to 1.3±0.70 (nmol/spot/hr) between the studies which was less than all control groups except cryptogenic cirrhosis patients (0.5±0.15 nmol/spot/hr). Of the other outcomes of interest, ALT, AST, total cholesterol, triglyceride and LDL cholesterol were found elevated in NAFLD patients than in controls.CONCLUSIONS
: The current evidence suggests a potential correlation of reduced LAL activity with NAFLD pathogenesis according to its severity. Large-scale studies are recommended, more importantly in NAFLD patients having no metabolic or genetic involvement. Further LAL can act as a new non-invasive diagnostic biomarker to identify that specific NAFLD subgroup.Conference/Value in Health Info
Value in Health, Volume 25, Issue 6, S1 (June 2022)
Code
RWD116
Topic
Clinical Outcomes, Epidemiology & Public Health, Patient-Centered Research, Study Approaches
Topic Subcategory
Clinical Outcomes Assessment, Literature Review & Synthesis, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Gastrointestinal Disorders